Try our beta test site
IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more...
133 studies found for:    IGF1R
Show Display Options
Rank Status Study
1 Not yet recruiting Predictive Biomarkers for IGF1R Targeted Therapy in Ovarian Cancer
Condition: Ovarian Cancer
Interventions: Biological: IGF1R antibody MK0646;   Other: Saline solution
2 Completed Retrospective Study Evaluating IGF1R And p95HER2 as Prognostic Factors in Non Small Cell Lung Cancer (NSCLC)
Condition: Non Small Cell Lung Cancer
Intervention: Genetic: Protein expression by immunohistochemistry and immunofluorescence
3 Not yet recruiting In Vivo IGF-1R Molecular Imaging Using [68Ga]- Labelling Anti-IGF-1R Affibody Molecule
Condition: Molecular Imaging
Intervention: Radiation: 68Ga-NODAGA-ZIGF-1R:4:40
4 Not yet recruiting Predictive Biomarkers for IGF1R Targeted Therapy in Ovarian Cancer: a Retrospective Study
Condition: Ovarian Cancer
Intervention: Other: Immunohistochemistry staining method
5 Completed Phase 1 Study of BIIB022 (Anti-IGF-1R Monoclonal Antibody) in Relapsed/Refractory Solid Tumors
Condition: Solid Tumors
Intervention: Drug: BIIB022
6 Completed Study of AVE1642 Anti-IGF1R Monoclonal Antibody in Patients With Advanced Multiple Myeloma
Condition: Multiple Myeloma
Interventions: Drug: AVE1642;   Drug: Velcade
7 Active, not recruiting
Has Results
A Randomized Phase II Study of Cisplatin and Etoposide in Combination With Either Hedgehog Inhibitor GDC-0449 or IGF-1R MOAB IMC-A12 for Patients With Extensive Stage
Conditions: Extensive Stage Small Cell Lung Carcinoma;   Recurrent Small Cell Lung Carcinoma
Interventions: Drug: Cisplatin;   Biological: Cixutumumab;   Drug: Etoposide;   Other: Laboratory Biomarker Analysis;   Drug: Vismodegib
8 Suspended Clinical Study of Oral IGF-1R Inhibitor in Subjects With Advanced Refractory Solid Tumors
Condition: Advanced Refractory Solid Tumors
Intervention: Drug: PL225B
9 Terminated Study of AVE1642 (IGF-1R/CD221) in Combination With Fulvestrant (Faslodex®) in Postmenopausal Patients With Advanced Hormono-dependent Breast Cancer
Condition: Breast Neoplasms
Interventions: Drug: AVE1642;   Drug: Fulvestrant
10 Terminated
Has Results
IMC-A12 With Mitotane vs Mitotane Alone in Recurrent, Metastatic, or Primary ACC That Cannot Be Removed by Surgery
Conditions: Recurrent Adrenocortical Carcinoma;   Stage III Adrenocortical Carcinoma;   Stage IV Adrenocortical Carcinoma
Interventions: Biological: IMC-A12;   Drug: mitotane
11 Completed A Study to Evaluate the Biological Activity of R1507 in Women With Operable Breast Cancer
Condition: Breast Cancer
Intervention: Drug: RG1507
12 Completed A Study of the IGF-1R Inhibitor AXL1717 in Combination With Gemcitabine HCL and Carboplatin to Treat Non-small-cell Lung Cancer (NSCLC)
Condition: Non Small Cell Lung Cancer
Intervention: Drug: AXL1717
13 Unknown  Study of IGF-Methotrexate Conjugate in the Treatment of Advanced Tumors Expressing IGF-1R
Conditions: Breast Cancer;   Brain Cancer;   Gastrointestinal Cancers;   Genitourinary Cancers;   Gynecologic Cancers;   Head and Neck Cancers;   Melanoma;   Thoracic Cancers
Intervention: Drug: IGF-Methotrexate
14 Recruiting Insulin-like Growth Factor 1 Receptor (IGF-1R) Antibody AMG479 (Ganitumab) in Combination With the Src Family Kinase (SFK) Inhibitor Dasatinib in People With Embryonal and Alveolar Rhabdomyosarcoma
Conditions: Rhabdomyosarcoma;   Rhabdomyosarcoma- Alveolar;   Rhabdomyosarcoma-Embryonal
Interventions: Drug: Dasatinib;   Drug: Ganitumab
15 Terminated Dose Finding Study of AVE1642 in Patients With Advanced or Metastatic Liver Carcinoma
Condition: Liver Carcinoma
Interventions: Drug: AVE1642;   Drug: sorafenib;   Drug: erlotinib
16 Completed Cixutumumab and Sorafenib Tosylate in Treating Patients With Advanced Liver Cancer
Conditions: Adult Hepatocellular Carcinoma;   Advanced Adult Hepatocellular Carcinoma;   Localized Non-Resectable Adult Liver Carcinoma;   Recurrent Adult Liver Carcinoma
Interventions: Biological: Cixutumumab;   Other: Laboratory Biomarker Analysis;   Drug: Sorafenib Tosylate
17 Completed A Dose Escalating Clinical Trial of the IGF-1 Receptor Inhibitor AXL1717 in Patients With Advanced Cancer
Condition: Solid Tumors
Intervention: Drug: AXL1717
18 Withdrawn Phase 2, Endocrine Therapy + OSI-906 With or Without Erlotinib for Hormone-sensitive Metastatic Breast Cancer
Condition: Breast Cancer
Interventions: Drug: IGF-1R inhibitor OSI-906;   Drug: erlotinib hydrochloride;   Drug: goserelin;   Drug: letrozole
19 Recruiting Antisense102: Pilot Immunotherapy for Newly Diagnosed Malignant Glioma
Conditions: Malignant Glioma;   Neoplasms
Interventions: Drug: IGF-1R/AS ODN; Surgery with tissue harvest and implantation 10 diffusion chambers in the rectus sheath with IGF-1R/AS ODN within 24 hours of craniotomy, implanted for 24 hours.;   Drug: IGF-1R/AS ODN; Surgery with tissue harvest and implantation 10 diffusion chambers in the rectus sheath with IGF-1R/AS ODN within 24 hours of craniotomy, implanted for 48 hours.;   Drug: IGF-1R/AS ODN; Surgery with tissue harvest and implantation of 20 diffusion chambers in the rectus sheath with IGF-1R/AS ODN within 24 hours of craniotomy, implanted for 24 hours.;   Drug: IGF-1R/AS ODN; Surgery with tissue harvest and implantation of 20 diffusion chambers in the rectus sheath with IGF-1R/AS ODN within 24 hours of craniotomy, implanted for 48 hours.
20 Active, not recruiting Studying Tissue Samples From Women With Breast Cancer Who Were Treated on Clinical Trial NCCTG-N9831
Condition: Breast Cancer
Intervention: Other: diagnostic laboratory biomarker analysis

   Previous Page Studies Shown (1-20) Next Page (21-40) Show next page of results    Last Page
Study has passed its completion date and status has not been verified in more than two years.